Biocon Share Price in Focus on May 9; Net Profit Surges 153% in Q4FY25 Results

Biocon Limited announced its consolidated financial results for the fourth quarter and full financial year ended March 31, 2025, highlighting a robust performance in Q4 and stable growth over FY25.

Post the announcement, on May 9, 2025, Biocon share price opened at ₹333.50, down from its previous close of ₹334.60. At 10:15 AM, the share price of Biocon was trading at ₹333.65, down by 0.28% on the NSE.

Q4FY25 Financial Highlights

In the fourth quarter of FY25, Biocon posted a consolidated total revenue of ₹4,454 crore, reflecting a 12% year-on-year (YoY) increase and a 15% sequential growth. On a like-for-like basis (excluding Branded Formulations India or BFI), the revenue grew by 15% YoY.

The company reported a jump in its profitability. Net profit for the quarter stood at ₹344 crore, marking a 153% increase YoY. This profit growth was supported by higher operational efficiencies and reduced exceptional costs. Profit Before Tax (PBT) came in at ₹487 crore, up 53% YoY.

Biocon’s EBITDA for the quarter was ₹1,115 crore, up 16%, with a margin of 25%. Core EBITDA stood at ₹1,363 crore, also showing a 16% rise with a core operating margin of 31%. The company continued its investment in innovation, with R&D expenses of ₹231 crore, accounting for 7% of revenues ex-Syngene.

FY25 Financial Highlights

For the full financial year, Biocon reported consolidated revenue of ₹16,470 crore, representing a 5% YoY growth. On a like-for-like basis (adjusting for BFI divestment and Bicara stake dilution gains), the revenue growth was 8% YoY.

Core EBITDA for the year stood at ₹4,264 crore, up 2%, with a core operating margin of 28%. The overall EBITDA was ₹4,374 crore, reflecting a 5% YoY growth, with margins holding steady at 27%.

Despite the one-time gains in the previous year, Biocon maintained its bottom line, reporting a net profit of ₹1,013 crore, close to last year’s ₹1,022 crore.

Dividend Announcement

Biocon’s Board of Directors recommended a final dividend of ₹0.50 per equity share, or 10% of the face value, for FY25.

Also Read:Biocon Board Greenlights Fundraising Plan of Up to ₹4,500 Crore!

Conclusion

Biocon ended FY25 with profit growth and operating margins. The company’s continued focus on R&D, along with strategic divestments and operational improvements.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.